Difference between revisions of "Paclitaxel (Taxol)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
 
(14 intermediate revisions by 2 users not shown)
Line 18: Line 18:
 
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
 
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
 
*[[Anal cancer]]
 
*[[Anal cancer]]
−
*[[Bladder cancer]]
+
*[[Angiosarcoma]]
 
*[[Carcinoma of unknown primary]]
 
*[[Carcinoma of unknown primary]]
 
*[[Cervical cancer]]
 
*[[Cervical cancer]]
 
*[[Cutaneous basal cell carcinoma]]
 
*[[Cutaneous basal cell carcinoma]]
 
*[[Diffuse large B-cell lymphoma]]
 
*[[Diffuse large B-cell lymphoma]]
 +
*[[Endometrial cancer]]
 
*[[Esophageal cancer]]
 
*[[Esophageal cancer]]
 
**[[Esophageal adenocarcinoma]]
 
**[[Esophageal adenocarcinoma]]
Line 28: Line 29:
 
*[[Gastric cancer]]
 
*[[Gastric cancer]]
 
*[[Head and neck cancer]]
 
*[[Head and neck cancer]]
−
*[[Melanoma]]  
+
*[[Melanoma]]
 +
*[[Nasopharyngeal carcinoma]]
 
*[[Penile cancer]]
 
*[[Penile cancer]]
 
*[[Prostate cancer]]
 
*[[Prostate cancer]]
Line 34: Line 36:
 
*[[Testicular cancer]]
 
*[[Testicular cancer]]
 
*[[Thymoma]]
 
*[[Thymoma]]
−
*[[Endometrial cancer]]
+
*[[Urothelial carcinoma]]
−
*[[Vascular sarcoma]]
+
**[[Bladder cancer]]
 
*[[Vulvar cancer]]
 
*[[Vulvar cancer]]
 
</div>
 
</div>
 
==Patient drug information==
 
==Patient drug information==
 
*[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf Paclitaxel (Taxol) package insert]<ref name="insert"></ref>
 
*[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf Paclitaxel (Taxol) package insert]<ref name="insert"></ref>
−
*[https://chemocare.com/chemotherapy/drug-info/Paclitaxel.aspx Paclitaxel (Taxol) patient drug information (Chemocare)]<ref>[https://chemocare.com/chemotherapy/drug-info/Paclitaxel.aspx Paclitaxel (Taxol) patient drug information (Chemocare)]</ref>
+
*[https://chemocare.com/druginfo/Paclitaxel.aspx Paclitaxel (Taxol) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/Paclitaxel.aspx Paclitaxel (Taxol) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]</ref>
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
* 12/29/1992: Initial FDA approval for treatment of patients with metastatic [[Ovarian cancer|carcinoma of the ovary]] after failure of first-line or subsequent chemotherapy. ''(Based on Eisenhauer et al. 1994)''
+
===[[Breast cancer]]===
−
* 4/9/1998 (oldest label available at Drugs@FDA): Indicated for first-line and subsequent therapy for the treatment of advanced [[Ovarian cancer | carcinoma of the ovary]]. As first-line therapy, Taxol is indicated in combination with [[Cisplatin (Platinol) | cisplatin]]. ''(Based on GOG 111 & OV10)''
+
* 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the treatment of [[Breast cancer | breast cancer]] after failure of combination therapy for metastatic disease. Prior therapy should have included an [[:Category:Anthracyclines|anthracycline]] unless clinically contraindicated. ''(Based on Nabholtz et al. 1996)''
−
* 4/9/1998 (oldest label available at Drugs@FDA): Indicated for the treatment of [[Breast cancer | breast cancer]] after failure of combination therapy for metastatic disease or relapsed within 6 months of adjuvant chemotherapy. Prior therapy should have included an [[:Category:Anthracyclines|anthracycline]] unless clinically contraindicated. ''(Based on Nabholtz et al. 1996)''
+
* 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the treatment of [[Breast cancer | breast cancer]] relapsed within 6 months of adjuvant chemotherapy. Prior therapy should have included an [[:Category:Anthracyclines|anthracycline]] unless clinically contraindicated. ''(Based on Nabholtz et al. 1996)''
−
* 4/9/1998 (oldest label available at Drugs@FDA): Indicated for the second-line treatment of [[Kaposi sarcoma | AIDS-related Kaposi's sarcoma]]. ''(Based on CA139-174 & CA139-281)''
+
* 1999-10-25: New indication for the adjuvant treatment of node-positive [[Breast cancer | breast cancer]] administered sequentially to standard [[Doxorubicin (Adriamycin) | doxorubicin]]-containing combination chemotherapy. ''(Based on INT 0148/CALGB 9344)''
−
* 6/30/1998: New indication added: in combination with [[Cisplatin (Platinol) | cisplatin]], is indicated for the first-line treatment of [[Non-small cell lung cancer | non-small cell lung cancer]] in patients who are not candidates for potentially curative surgery and/or radiation therapy. ''(Based on ECOG E5592)''
+
===[[Ovarian cancer]]===
−
* 10/25/1999: New indication for the adjuvant treatment of node-positive [[Breast cancer | breast cancer]] administered sequentially to standard [[Doxorubicin (Adriamycin) | doxorubicin]]-containing combination chemotherapy. ''(Based on INT 0148/CALGB 9344)''
+
* 1992-12-29: Initial FDA approval for treatment of patients with metastatic [[Ovarian cancer|carcinoma of the ovary]] after failure of first-line or subsequent chemotherapy. ''(Based on Eisenhauer et al. 1994)''
 +
* 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for first-line therapy in combination with [[Cisplatin (Platinol) | cisplatin]] for the treatment of advanced [[Ovarian cancer | carcinoma of the ovary]]. ''(Based on GOG 111 & OV10)''
 +
* 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for subsequent therapy for the treatment of advanced [[Ovarian cancer | carcinoma of the ovary]]. ''(Based on GOG 111 & OV10)''
 +
===[[Kaposi sarcoma]]===
 +
* 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the second-line treatment of [[Kaposi sarcoma | AIDS-related Kaposi's sarcoma]]. ''(Based on CA139-174 & CA139-281)''
 +
===[[Non-small cell lung cancer]]===
 +
* 1998-06-30: New indication added: in combination with [[Cisplatin (Platinol) | cisplatin]], is indicated for the first-line treatment of [[non-small cell lung cancer]] in patients who are not candidates for potentially curative surgery and/or radiation therapy. ''(Based on ECOG E5592)''
 +
==History of changes in EMA indication==
 +
*1992-12-29: EURD
 +
==History of changes in PMDA indication==
 +
*2005-05-31: New indication for the treatment of [[endometrial cancer|cancer of the uterus body]].
 +
*2012-03-21: New additional indications and new dosages for the treatment of relapsed or metastatic [[head and neck cancer]].
 +
*2012-03-21: New additional indications and new dosages for the treatment of relapsed or metastatic [[Esophageal cancer|esophagus cancer]].
 +
*2012-03-21: New additional indications and new dosages for the treatment of [[angiosarcoma]].
 +
*2012-03-21: New additional indications and new dosages for the treatment of advanced or relapsed [[cervical cancer]].
 +
*2013-02-21: New additional indications and a new dosage for the treatment of relapsed or refractory germ cell tumors (testicular tumors, ovarian tumors, extragonadal tumors).
  
 
==Also known as==
 
==Also known as==
Line 102: Line 119:
 
|-
 
|-
 
|Paxus
 
|Paxus
 +
|Pazenir
 
|Petaxel
 
|Petaxel
 
|Phyxol
 
|Phyxol
Line 108: Line 126:
 
|Ribotax
 
|Ribotax
 
|Sindaxel
 
|Sindaxel
 +
|-
 
|Taclipaxol
 
|Taclipaxol
−
|-
 
 
|Tarvexol
 
|Tarvexol
 
|Taxocris
 
|Taxocris
Line 117: Line 135:
 
|Taycovit
 
|Taycovit
 
|Unitaxel
 
|Unitaxel
 +
|-
 
|Yewtaxan
 
|Yewtaxan
 +
|Naveruclif
 
|-
 
|-
 
|}
 
|}
Line 134: Line 154:
  
 
[[Category:Anal cancer medications]]
 
[[Category:Anal cancer medications]]
 +
[[Category:Angiosarcoma medications]]
 
[[Category:Bladder cancer medications]]
 
[[Category:Bladder cancer medications]]
 
[[Category:Breast cancer medications]]
 
[[Category:Breast cancer medications]]
Line 149: Line 170:
 
[[Category:Low-grade serous ovarian cancer medications]]
 
[[Category:Low-grade serous ovarian cancer medications]]
 
[[Category:Melanoma medications]]  
 
[[Category:Melanoma medications]]  
 +
[[Category:Nasopharyngeal carcinoma medications]]
 
[[Category:Non-small cell lung cancer medications]]
 
[[Category:Non-small cell lung cancer medications]]
 
[[Category:Non-small cell lung cancer, nonsquamous medications]]
 
[[Category:Non-small cell lung cancer, nonsquamous medications]]
Line 158: Line 180:
 
[[Category:Testicular cancer medications]]
 
[[Category:Testicular cancer medications]]
 
[[Category:Thymoma medications]]
 
[[Category:Thymoma medications]]
−
[[Category:Vascular sarcoma medications]]  
+
[[Category:Urothelial carcinoma medications]]
 
[[Category:Vulvar cancer medications]]
 
[[Category:Vulvar cancer medications]]
  
 
[[Category:FDA approved in 1992]]
 
[[Category:FDA approved in 1992]]
 +
[[Category:EMA approved in 1992]]
 
[[Category:PMDA approved drugs]]
 
[[Category:PMDA approved drugs]]
 
[[Category:WHO Essential Cancer Medicine]]
 
[[Category:WHO Essential Cancer Medicine]]

Latest revision as of 17:50, 19 November 2023

General information

Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. Paclitaxel is highly lipophilic/insoluble in water and needs to be dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.[1][2]
Route: IV
Extravasation: irritant (usually), vesicant (rare)

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Breast cancer

  • 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the treatment of breast cancer after failure of combination therapy for metastatic disease. Prior therapy should have included an anthracycline unless clinically contraindicated. (Based on Nabholtz et al. 1996)
  • 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the treatment of breast cancer relapsed within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. (Based on Nabholtz et al. 1996)
  • 1999-10-25: New indication for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. (Based on INT 0148/CALGB 9344)

Ovarian cancer

  • 1992-12-29: Initial FDA approval for treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. (Based on Eisenhauer et al. 1994)
  • 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for first-line therapy in combination with cisplatin for the treatment of advanced carcinoma of the ovary. (Based on GOG 111 & OV10)
  • 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for subsequent therapy for the treatment of advanced carcinoma of the ovary. (Based on GOG 111 & OV10)

Kaposi sarcoma

  • 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the second-line treatment of AIDS-related Kaposi's sarcoma. (Based on CA139-174 & CA139-281)

Non-small cell lung cancer

  • 1998-06-30: New indication added: in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. (Based on ECOG E5592)

History of changes in EMA indication

  • 1992-12-29: EURD

History of changes in PMDA indication

  • 2005-05-31: New indication for the treatment of cancer of the uterus body.
  • 2012-03-21: New additional indications and new dosages for the treatment of relapsed or metastatic head and neck cancer.
  • 2012-03-21: New additional indications and new dosages for the treatment of relapsed or metastatic esophagus cancer.
  • 2012-03-21: New additional indications and new dosages for the treatment of angiosarcoma.
  • 2012-03-21: New additional indications and new dosages for the treatment of advanced or relapsed cervical cancer.
  • 2013-02-21: New additional indications and a new dosage for the treatment of relapsed or refractory germ cell tumors (testicular tumors, ovarian tumors, extragonadal tumors).

Also known as

  • Brand names:
Synonyms
Abitaxel Altaxel Anzatax Anzatec Apealea Asotax Betaxel Bristaxol
Britaxol Clitaxel Cytax Daburex Dalys Drifen Ebetaxel Formoxol
Genexol Genetaxyl Gros Ifaxol Intaxel Magytax Medixel Mitotax
Neotacs Neotaxan Neotaxl Ofoxel Oncotaxel Onxol Paclitax Paclitaxin
Pacliteva Pacxel Padexol Paklitaxfil Panataxel Parexel Paxene Paxenor
Paxus Pazenir Petaxel Phyxol Poltaxel Praxel Ribotax Sindaxel
Taclipaxol Tarvexol Taxocris Taxodiol Taxol Taxomedac Taycovit Unitaxel
Yewtaxan Naveruclif

References

  1. ↑ 1.0 1.1 1.2 Paclitaxel (Taxol) package insert
  2. ↑ Paclitaxel (Taxol) package insert (locally hosted backup)
  3. ↑ Paclitaxel (Taxol) patient drug information (Chemocare)
  4. ↑ Paclitaxel (Taxol) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Paclitaxel_(Taxol)&oldid=80765"